nyra health raises €20 million to expand into the leading AI platform for neurotherapy

nyra health, provider of an AI-powered platform for neurological therapy, has successfully closed a €20 million Series A funding round. The investment was led by Armira Growth, a European growth investor known for its strong footprint in the healthcare and technology sectors. Existing backers, including Wellington Partners, Crane Venture Partners (which now manages MassMutual Ventures’ portfolio), and EVER Pharma, have also reaffirmed their support by participating in the round.

The Vienna-based company plans to use the new funding to further scale its technology platform across the DACH region, accelerate its expansion into the U.S. market, and advance its mission of setting a new benchmark for data-driven neuro-rehabilitation.

‍

Moritz Schöllauf,CEO and co-founder, nyra health:"From the outset, our goal was to make our services widely available to those affected. Everyone who needs therapy after a stroke or other neurological disease should have access to effective, individualized care—regardless of where they live or how well their own healthcare system is set up. With this round of financing, we are taking another step in this direction."

Christian Figge,Managing Partner, Armira Growth: "Neurological rehabilitation can be made significantly more effective through digital solutions, especially in the area of speech ability. nyra health is considered a true category creator with a proprietary AI-based solution that seamlessly connects the entire care chain—from inpatient therapy to outpatient aftercare to home use—for the first time. We were also particularly impressed by the strong clinical evidence and deep integration into the German standard of care, which already gives nyra health access to over 40 million insured individuals.On this basis, the company is ideally positioned to define the market for digital neuro-rehabilitation internationally as well."

‍

Neurological diseases such as stroke, dementia, and traumatic brain injury cause €65 billion in costs annually in Germany alone, mainly because care often stops or significantly decreases in intensity after discharge from the hospital. The result is gaps in care for those affected and rising costs due to inadequate follow-up care and avoidable long-term consequences for health insurance companies and cost bearers.

nyra health closes this gap and enables continuous therapy from inpatient stay to long-term outpatient care. The AI-based platform myReha is now in use in over 100 neurological clinics, where it increases the available therapy density even during the patient's stay. Treatment does not end with discharge: nyra health is a recognized digital application that is part of the standard care provided by the German Pension Insurance, Europe's largest rehabilitation provider, and ensures structured follow-up treatment over several months.

In addition, myReha has been shown to significantly increase therapy time while delivering substantial cost savings: 28 statutory and private health insurance companies already automatically reimburse myReha. More than 40 million insured individuals now have access to structured, AI-based home therapy with real-time feedback, thereby reducing the burden on the cost-intensive healthcare system.

WithSeries A financing, nyra health is consistently continuing its growth course and is initially focusing on further market penetration. In the DACH region, additional clinic groups will be connected and existing reimbursement models inGermany, Austria, and Switzerland will be expanded in a targeted manner. At the same time, the company is preparing to enter the US market—together with an international pharmaceutical company with which a market launch in the UnitedStates is planned.

nyra health is also investing in the technological advancement of its platform. The focus is on expanding multimodal AI models for therapeutic interaction and diagnostics.These are being developed as part of a funded research project worth €4.2million and scientifically validated in collaboration with leading US research universities.

‍

‍